Table 1: Patient characteristics before Rituximab.
Patient number | Histological diagnosis from renal biopsy | Type of nephrotic syndrome | Sex | Age at disease diagnosis | Years of disease before treatment | Previous treatments | Use of ACEI or ARB before Rituximab |
1 | MCD | SDNS | M | 2 | 11 | Pred/TAC/MMF | No |
2 | MCD | SDNS | F | 3 | 15 | 2 MCD SDNS F 3 15 Pred/CsA/MMF/Oral CTX Yes | Yes |
3 | FSGS | SDNS | M | 2 | 18 | Pred/TAC/MMF/Oral CTX | No |
4 | FSGS | SDNS | F | 9 | 8 | Pred/TAC/MMF/Oral + IV CTX | No |
5 | MCD | SDNS | M | 4 | 13 | Pred/TAC/MMF | No |
6 | MCD | SDNS | M | 10 | 3 | Pred/TAC/MMF/Oral CTX | Yes |
7 | C1Q nephropathy with FSGS | SDNS | M | 2 | 2 | Pred/TAC/MMF/IV CTX | Yes |
8 | FSGS | SRNS | M | 2 | 11 | Pred/CsA/MMF | Yes |
9 | MCD | SDNS | M | 2 | 11 | Pred/CsA/MMF/Oral CTX | No |
10 | C1Q nephropathy | SRNS | F | 2 | 6 | Pred/TAC/MMF/Oral CTX | No |
11 | MCD | SDNS | M | 6 | 7 | Pred/CsA/MMF | No |
ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin Receptor Blocker; CsA: Cyclosporin A; CTX: Cyclophosphamide; FGS: Focal Glomerulosclerosis; FSGS: Focal Segmental Glomerulosclerosis; MCD: Minimal Change Disease; MMF: Mycophenolate Mofetil; Pred: Prednisolone; SDNS: Steroid Dependent Nephrotic Syndrome; SRNS: Steroid Resistant Nephrotic Syndrome; TAC: Tacrolimus.